/
We are a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. We are focused on expanding patient access, progressing our pipeline toward key milestones, and delivering meaningful therapeutics.
$11.40
+$0.45 (+4.11%)
Price from 6 days ago
The business is unprofitable at the operating level (-59.12% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 350.9% YoY with margins expanding 309.4pp.
Negative free cash flow of -$2M. The business is consuming cash, not generating it.
5.7x earnings, 57.2x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$122M
▲ +350.9% YoY
Net Income (TTM)
$124M
▲ +178.9% YoY
Op. Margin
-4.44%
▲ +309.4pp YoY
ROIC
-2.15%
▲ +50.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$12M
▲ +96.5% YoY
Op. Cash Flow (TTM)
$13M
▲ +97.7% YoY
Net Debt
-$199M
Net Cash Position
Cash & Equiv.
$201M
5Y CAGR: +51.6%
Continue Research